.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapies' $ 5.8 billion purchase to Bristol Myers Squibb in 2013, is taking the controls of young biotech Terremoto Biosciences.Baum's "extensive adventure in medicine development, as well as proven track record beforehand high-impact medicines, will be instrumental," outward bound CEO Peter Thompson, M.D., pointed out in a July 25 release. Thompson will certainly retain his chair as panel chairperson..Baum, a trained physician-scientist, was the creator, head of state and chief executive officer of oncology-focused Mirati. Prior to that, he assisted cultivate cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will serve as chief executive officer at Terremoto, a company establishing tiny molecules to target disease-causing proteins-- like those discovered in cancerous growth cells-- using covalent connections. Existing therapies that use covalent connections primarily target the amino acid cysteine. Nevertheless, of the 20 amino acids that make up proteins, cysteine is actually the least popular. Terremoto is actually instead targeting some of the important amino acids, lysine, which is located in mostly all healthy proteins.By targeting amino acid lysine and also various other amino acids, Terremoto plans to handle previously undruggable diseases as well as make first-in-class medications..The biotech, based in South San Francisco, brought up $75 thousand in series A funding in 2022. A little more than a year later on, the biotech much more than multiplied that variety in a $175 million series B.